## Supporting information for

## **ORIGINAL ARTICLE**

Cdk5 knocking out mediated by CRISPR-Cas9 genome editing for

## PD-L1 attenuation and enhanced antitumor immunity

Huan Deng<sup>a,†,</sup> Songwei Tan<sup>a,†</sup>, Xueqin Gao<sup>a</sup>, Chenming Zou<sup>a</sup>, Chenfeng Xu<sup>a</sup>, Kun Tu<sup>a</sup>, Qingle Song<sup>a</sup>, Fengjuan Fan<sup>b</sup>, Wei Huang<sup>c</sup>, Zhiping Zhang<sup>a,d,e,\*</sup>

<sup>a</sup>School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>b</sup>Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>c</sup>Department of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>d</sup>National Engineering Research Center for Nanomedicine, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>e</sup>Hubei Engineering Research Center for Novel Drug Delivery System, Huazhong University of Science and Technology, Wuhan 430030, China

<sup>†</sup>These authors made equal contributions to this work.

\*Corresponding author.

E-mail address: zhipingzhang@hust.edu.cn (Zhiping Zhang)

Target locus	Sequence	Primer F	Primer R
sgCdk5-1	CAGGCTGGAT	TCTGAAGACCCTA	GCCTCTAACATCC
	GATGACGATG	CTTGCAGTCCCA	CAATACCAGCCC
sgCdk5-2	GTGTGCCAAG	GCCTTTGCCCTGA	AGGCAAGTAGTCC
	TTCAGCCCTC	GAACTTACCCTT	TTGGTAGGCAGA
sgCdk5-3	CCGGGAAACT	CCTTAGCAATCTC	TTAGCCACATCTC
	CATGAGATTG	TGTGGACCAGCC	CAAGTTGGCCTC
sgCdk5-4	GGTCCCTATG	TTGTACTCCCACA	GCCAGGCCAAAAT
	TAGCACGTTG	CATCCCTCCAGT	CAGCCAATTTCA

**Table S1** Four potential target sites of *Cdk5* gene in mouse genome and the primers respectively.

**Table S2** Primers utilized for qRT-PCR analysis.

Target locus	Primer F	Primer R
Cdk5	ACAGCCGCAACGTGCTACAT AG	CATGTCGATGGACGTGGAG TACA
<i>p35</i>	AAGAACCTATCTGACATGCT GCTAT	ACAAAATTCTCCTGGTTCGC
PD-L1	AGCTACGGTGGTGCGGACTA	GGTGACACTTCTCTTCCCAC TCAC
GAPDH	GAGAGTGTTTCCTCGTCCCG TA	TGAGGTCAATGAAGGGGTC G

Table S3 Stability and zeta potential of aPBAE/Cas9-Cdk5 (	(80:1) in 24 h.
--	-----------------

	Diameter (nm)	$\zeta$ -potential (mV)
aPBAE/Cas9-Cdk5	246.3±30.1	23.8±2.0
aPBAE/Cas9-Cdk5 (after 24 h)	270.3±88.6	22.4±3.3

1 0	-			
Ratio	PBS	Naked pDNA	aPBAE/Cas9-null	aPBAE/Cas9-Cdk5
CD8 <sup>+</sup> to CD4 <sup>+</sup>	0.82	0.92	0.98	1.55
	0.87	1.20	1.08	2.02
	0.93	1.33	1.23	2.00
	0.92	0.74	0.87	1.65
CD4 <sup>+</sup> Foxp3 <sup>+</sup>	0.6	0.7	0.6	0.1
	0.5	0.6	0.3	0.1
	0.8	0.5	0.6	0.2
	0.6	0.6	0.5	0.2

**Table S4** Representative flow cytometry data about  $CD8^+$  to  $CD4^+$  ratio and percentage of  $CD4^+Foxp3^+$  cells.

**Table S5** The particle size characterization of aPBAE/Cas9-Cdk5 at different ratios.

No.	Diameter of particle (nm) at different ratio						
	10:1	20:1	40:1	60:1	80:1	100:1	120:1
1	242	288.2	118.8	185.4	138	285	276.3
2	294.4	401.2	232.2	250.6	181.6	301.8	336.5
3	358.1	490.6	246.4	266.7	196.3	319.5	358
4	529.9	599.8	261.4	283.9	212.2	338.3	380.8
5	644.6	683.3	277.4	302.1	259.3	358.2	445.2
6	435.6	480.5	394.4	351.6	313.1	379.3	370.9
Average	417.4	490.6	255.1	273.3	216.7	330.3	361.2



**Figure S1** The construction of four potential target sites of *Cdk5* gene sequences into pX330 vector.

A



**Figure S2** (A) Synthetic scheme of PBAE copolymer. (B) <sup>1</sup>H NMR spectra of PBAE and aPBAE (solvent:  $CDCl_3$ ).



**Figure S3** Scatter plots for the transfection efficiency of aPBAE/pMax-GFP with different weight ratios in B16F10 cells, PEI 25K and HP reagent used as controls.



**Figure S4** The transfection efficiency of aPBAE/pMax-GFP with different weight ratios in 4T1 cells, PEI 25K and HP reagent used as controls. The scale bar is 200 µm.



**Figure S5** Scatter plots for the transfection efficiency of aPBAE/pMax-GFP with different weight ratios in 4T1 cells, PEI 25K and HP reagent used as controls.



**Figure S6** Representative indel mutation sequences after aPBAE/Cas9-Cdk5 treatment *in vitro*.



**Figure S7** T7EI assay was performed from the tumor tissues of melanoma bearing mice after aPBAE/Cas9-Cdk5 treatment compared to PBS group *in vivo*.



**Figure S8** Survival rate of mice treated with PBS, naked pDNA, aPBAE/Cas9-Cdk5 and anti-PD-L1 antibody, respectively (n=10). Data were expressed as mean  $\pm$ SD. \*P < 0.05.



**Figure S9** CRISPR-Cas9 mediated PD-L1 attenuation suppressed B16F10 tumor growth. (A) Photographs of tumor dissected from C57BL/6 mice treated with PBS, aPBAE/Cas9-Cdk5 or anti-PD-L1 antibody (n=5). (B) Tumor weight of the mice (n=5). (C) Tumor growth curve of the mice after different treatments (n=5). Data were expressed as mean  $\pm$ SD. \*P<0.05, \*\*P<0.01, \*\*\*P<0.005.



**Figure S10** H&E staining sections of the B16F10 tumors after treatment. The scale bars are 200  $\mu$ m and 100  $\mu$ m respectively.



**Figure S11** H&E staining sections of the 4T1 tumors after treatment. The scale bars are 200  $\mu$ m and 100  $\mu$ m, respectively.



**Figure S12** Mice body weight after treatment. (A) B16F10 tumor model, C57BL/6 mice (n=6). (B) 4T1 tumor model, BALB/c mice (n=6). Data were expressed as mean ±SD.



**Figure S13** Scatter plots of CD4<sup>+</sup>Foxp3<sup>+</sup> cells in B16F10 tumors after treatment.



**Figure S14** Ratios of CD8<sup>+</sup> T cells to CD4<sup>+</sup>Foxp3<sup>+</sup> T cells and CD4<sup>+</sup>Foxp3<sup>-</sup> T cells to CD4<sup>+</sup>Foxp3<sup>+</sup> T cells in B16F10 tumors (n=6). Data were expressed as mean  $\pm$ SD. \**P*<0.05, \*\*\**P*<0.005



**Figure S15** Representative protein expression of IRF2 and IRF2BP2 in (A) melanoma (PBS (G1), naked pDNA (G2), aPBAE/Cas9-null (G3), aPBAE/Cas9-Cdk5 (G4)) and (B) breast cancer models (PBS (G1), naked pDNA (G2), aPBAE/Cas9-Cdk5 (G3), anti-PD-L1 antibody (G4)) after treatments.



**Figure S16** Serum chemistry indexes in C57BL/6 mice after treatment. (A) ALT, (B) AST, (C) BUN, (D) Cre and (E) LDH (n=6). Data were expressed as mean ±SD.



**Figure S17** H & E staining sections of organs from C57BL/6 mice after treatment. (A) PBS, (B) naked pDNA, (C) aPBAE/Cas9-null and (D) aPBAE/Cas9-Cdk5. The scale bars are 200  $\mu$ m.

Appendix S1 Deep sequencing of Cas9-Cdk5 plasmid.

AATGACGATCGCTCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGGGTG GGGTGGGGCAGGACAGCAAGGGGGGGGGGGGGGGAGGAAGAGAGAATAGCAGGCA TGCTGGGGAGCGGCCGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCT CTCTGCGCGCTCGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGA CCTGCAGGGGCGCCTGATGCGGTATTTTCTCCTTACGCATCTGTGCGGTATT TCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCAT TAAGCGCGGCGGGTGTGGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCC TCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGGCTCCCTTTAGGGTTCC GATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATG GTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTT GGAGTCCACGTTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACT CAACTCTATCTCGGGCTATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGG TCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAATTTTAA CAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCT GATGCCGCATAGTTAAGCCAGCCCGACACCCGCCAACACCCGCTGACGC

GCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGAC CGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACG CGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATG ATAATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGGAAATGTGCGC **GGAACCCCTATTTGTTTATTTTTCTAAATACATTCAAATATGTATCCGCTCATG** AGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTATG AGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCT TCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGA TCAGTTGGGTGCACGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAA GATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTT TAAAGTTCTGCTATGTGGCGCGGGTATTATCCCGTATTGACGCCGGGCAAGAG CAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCA CCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGC ACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGA AAACGACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGC GCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAAT AGACTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCC TTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGAA GCCGCGGTATCATTGCAGCACTGGGGGCCAGATGGTAAGCCCTCCCGTATCG TAGTTATCTACACGACGGGGGGGGGGGGCAGTCAGGCAACTATGGATGAACGAAATAGAC AGATCGCTGAGATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACC AAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTTAATTTAAAA GGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACG TGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATC CCACCCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAGCTACCAACTCT TTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCT TCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCC TACATACCTCGCTCTGCTAATCCTGTTACCAGTGGCTGCTGCCAGTGGCGAT AAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAGGCG CAGCGGTCGGGCTGAACGGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCG AACGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCG CCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCCGGTAAGCGGCAGG GTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGT ATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTT CCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTGAGGGCC TATTTCCCATGATTCCTTCATATTTGCATATACGATACAAGGCTGTTAGAGAG ATAATTGGAATTAATTTGACTGTAAACACAAAGATATTAGTACAAAATACGT GACGTAGAAAGTAATAATTTCTTGGGTAGTTTGCAGTTTTAAAATTATGTTTT AAAATGGACTATCATATGCTTACCGTAACTTGAAAGTATTTCGATTTCTTGG CTTTATATATCTTGTGGAAAGGACGAAACACCGGGTCCCTATGTAGCACGTT

GGTTTTAGAGCTAGAAATAGCAAGTTAAAATAAGGCTAGTCCGTTATCAAC TTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTGTTTTAGAGCTAGAAATAG CAAGTTAAAATAAGGCTAGTCCGTTTTTAGCGCGTGCGCCAATTCTGCAGA CAAATGGCTCTAGAGGTACCCGTTACATAACTTACGGTAAATGGCCCGCCT GGCTGACCGCCCAACGACCCCCGCCCATTGACGTCAATAGTAACGCCAATA GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCAC TTGGCAGTACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCA ATGACGGTAAATGGCCCGCCTGGCATTGTGCCCAGTACATGACCTTATGGG ACTTTCCTACTTGGCAGTACATCTACGTATTAGTCATCGCTATTACCATGGTC CCCCCAATTTTGTATTTATTTATTTTTTAATTATTTTGTGCAGCGATGGGGGC GCGCTCCGAAAGTTTCCTTTTATGGCGAGGCGGCGGCGGCGGCGGCGGCCCTAT CCGTGCCCGGCCGCCGCCGCCGCCGCCGCCCGGCCCGGCTCTGACTG GGTATTAATGTTTAATTACCTGGAGCACCTGCCTGAAATCACTTTTTTCAG GTTGGACCGGTGCCACCATGGACTATAAGGACCACGACGAGACTACAAG GATCATGATATTGATTACAAAGACGATGACGATAAGATGGCCCCAAAGAAG AAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCCGACAAGAAGTACAG CGAGTACAAGGTGCCCAGCAAGAAATTCAAGGTGCTGGGCAACACCGACC GGCACAGCATCAAGAAGAACCTGATCGGAGCCCTGCTGTTCGACAGCGGC GAAACAGCCGAGGCCACCCGGCTGAAGAAGAACCGCCAGAAGAAGAAGAACA CCAGACGGAAGAACCGGATCTGCTATCTGCAAGAGATCTTCAGCAACGAG GGTGGAAGAGGATAAGAAGCACGAGCGGCACCCCATCTTCGGCAACATCG TGGACGAGGTGGCCTACCACGAGAAGTACCCCACCATCTACCACCTGAGA GGCCCTGGCCCACATGATCAAGTTCCGGGGGCCACTTCCTGATCGAGGGCGA CCTGAACCCCGACAACAGCGACGTGGACAAGCTGTTCATCCAGCTGGTGC AGACCTACAACCAGCTGTTCGAGGAAAACCCCATCAACGCCAGCGGCGTG GACGCCAAGGCCATCCTGTCTGCCAGACTGAGCAAGAGCAGACGGCTGGA AAATCTGATCGCCCAGCTGCCCGGCGAGAAGAAGAATGGCCTGTTCGGAA ACCTGATTGCCCTGAGCCTGGGCCTGACCCCCAACTTCAAGAGCAACTTCG ACCTGGCCGAGGATGCCAAACTGCAGCTGAGCAAGGACACCTACGACGAC GACCTGGACAACCTGCTGGCCCAGATCGGCGACCAGTACGCCGACCTGTT TCTGGCCGCCAAGAACCTGTCCGACGCCATCCTGCTGAGCGACATCCTGAG AGTGAACACCGAGATCACCAAGGCCCCCTGAGCGCCTCTATGATCAAGA GATACGACGAGCACCACGAGGACCTGACCCTGCTGAAAGCTCTCGTGCGG CAGCAGCTGCCTGAGAAGTACAAAGAGATTTTCTTCGACCAGAGCAAGAA CGGCTACGCCGGCTACATTGACGGCGGAGCCAGCCAGGAAGAGTTCTACA

AGTTCATCAAGCCCATCCTGGAAAAGATGGACGGCACCGAGGAACTGCTC GTGAAGCTGAACAGAGAGGACCTGCTGCGGAAGCAGCGGACCTTCGACA ACGGCAGCATCCCCCACCAGATCCACCTGGGAGAGCTGCACGCCATTCTGC GGCGGCAGGAAGATTTTTACCCATTCCTGAAGGACAACCGGGAAAAGATC GAGAAGATCCTGACCTTCCGCATCCCCTACTACGTGGGCCCTCTGGCCAGG GGAAACAGCAGATTCGCCTGGATGACCAGAAAGAGCGAGGAAACCATCAC CCCCTGGAACTTCGAGGAAGTGGTGGACAAGGGCGCTTCCGCCCAGAGCT TCATCGAGCGGATGACCAACTTCGATAAGAACCTGCCCAACGAGAAGGTG CTGCCCAAGCACAGCCTGCTGTACGAGTACTTCACCGTGTATAACGAGCTG ACCAAAGTGAAATACGTGACCGAGGGAATGAGAAAGCCCGCCTTCCTGAG CGGCGAGCAGAAAAAGGCCATCGTGGACCTGCTGTTCAAGACCAACCGGA AAGTGACCGTGAAGCAGCTGAAAGAGGACTACTTCAAGAAAATCGAGTGC TTCGACTCCGTGGAAATCTCCGGCGTGGAAGATCGGTTCAACGCCTCCCTG GGCACATACCACGATCTGCTGAAAATTATCAAGGACAAGGACTTCCTGGAC AATGAGGAAAACGAGGACATTCTGGAAGATATCGTGCTGACCCTGACACT GTTTGAGGACAGAGAGAGATGATCGAGGAACGGCTGAAAACCTATGCCCACC TGTTCGACGACAAAGTGATGAAGCAGCTGAAGCGGCGGAGATACACCGGC TGGGGCAGGCTGAGCCGGAAGCTGATCAACGGCATCCGGGACAAGCAGTC CGGCAAGACAATCCTGGATTTCCTGAAGTCCGACGGCTTCGCCAACAGAA ACTTCATGCAGCTGATCCACGACGACAGCCTGACCTTTAAAGAGGACATCC AGAAAGCCCAGGTGTCCGGCCAGGGCGATAGCCTGCACGAGCACATTGCC AATCTGGCCGGCAGCCCGCCATTAAGAAGGGCATCCTGCAGACAGTGAA GGTGGTGGACGAGCTCGTGAAAGTGATGGGCCCGGCACAAGCCCGAGAAC ATCGTGATCGAAATGGCCAGAGAGAGAACCAGACCACCCAGAAGGGACAGA AGAACAGCCGCGAGAGAATGAAGCGGATCGAAGAGGGCATCAAAGAGCT GGGCAGCCAGATCCTGAAAGAACACCCCGTGGAAAACACCCCAGCTGCAG AACGAGAAGCTGTACCTGTACTACCTGCAGAATGGGCGGGGATATGTACGTG GACCAGGAACTGGACATCAACCGGCTGTCCGACTACGATGTGGACCATATC GTGCCTCAGAGCTTTCTGAAGGACGACTCCATCGACAACAAGGTGCTGAC CAGAAGCGACAAGAACCGGGGGCAAGAGCGACAACGTGCCCTCCGAAGAG GTCGTGAAGAAGATGAAGAACTACTGGCGGCAGCTGCTGAACGCCAAGCT GATTACCCAGAGAAAGTTCGACAATCTGACCAAGGCCGAGAGAGGCGGCC TGAGCGAACTGGATAAGGCCGGCTTCATCAAGAGACAGCTGGTGGAAACC CGGCAGATCACAAAGCACGTGGCACAGATCCTGGACTCCCGGATGAACAC TAAGTACGACGAGAATGACAAGCTGATCCGGGAAGTGAAAGTGATCACCC TGAAGTCCAAGCTGGTGTCCGATTTCCGGAAGGATTTCCAGTTTTACAAAG TGCGCGAGATCAACAACTACCACCACGCCCACGACGCCTACCTGAACGCC GTCGTGGGAACCGCCCTGATCAAAAAGTACCCTAAGCTGGAAAGCGAGTT CGTGTACGGCGACTACAAGGTGTACGACGTGCGGAAGATGATCGCCAAGA GCGAGCAGGAAATCGGCAAGGCTACCGCCAAGTACTTCTTCTACAGCAAC ATCATGAACTTTTTCAAGACCGAGATTACCCTGGCCAACGGCGAGATCCGG AAGCGGCCTCTGATCGAGACAAACGGCGAAACCGGGGGAGATCGTGTGGGA TAAGGGCCGGGATTTTGCCACCGTGCGGAAAGTGCTGAGCATGCCCCAAG TGAATATCGTGAAAAAGACCGAGGTGCAGACAGGCGGCTTCAGCAAAGAG CTGGGACCCTAAGAAGTACGGCGGCTTCGACAGCCCCACCGTGGCCTATTC TGTGCTGGTGGTGGCCAAAGTGGAAAAGGGCAAGTCCAAGAAACTGAAG AGTGTGAAAGAGCTGCTGGGGGATCACCATCATGGAAAGAAGCAGCTTCGA GAAGAATCCCATCGACTTTCTGGAAGCCAAGGGCTACAAAGAAGTGAAAA AGGACCTGATCATCAAGCTGCCTAAGTACTCCCTGTTCGAGCTGGAAAACG GCCGGAAGAGAATGCTGGCCTCTGCCGGCGAACTGCAGAAGGGAAACGA GAGAAGCTGAAGGGCTCCCCCGAGGATAATGAGCAGAAACAGCTGTTTGT GGAACAGCACAAGCACTACCTGGACGAGATCATCGAGCAGATCAGCGAGT TCTCCAAGAGAGTGATCCTGGCCGACGCTAATCTGGACAAAGTGCTGTCCG CCTACAACAAGCACCGGGATAAGCCCATCAGAGAGCAGGCCGAGAATATC ATCCACCTGTTTACCCTGACCAATCTGGGAGCCCCTGCCGCCTTCAAGTAC TTTGACACCACCATCGACCGGAAGAGGTACACCAGCACCAAAGAGGTGCT GGACGCCACCCTGATCCACCAGAGCATCACCGGCCTGTACGAGACACGGA TCGACCTGTCTCAGCTGGGAGGCGACAAAAGGCCGGCGGCCACGAAAAA GGCCGGCCAGGCAAAAAAGAAAAGTAAGAATTCCTAGAGCTCGCTGATC AGCCTCGACTGTGCCTTCTAGTTGCCAGCCATCTGTTGTTGCCCCCTCCCCC GTGCCTTCCTTGACCCTGGAAGGTGCCACTCCCACTGTCCTTTCCTAATAA AATGAGGAAATTGCATCGCATTGTCTGAGTAGGTGTCATTCTATTCTGGGGGG GTGGGGTGGGGCAGGACAGCAAGGGGGGGGGGGGGGAGGAAGAGAGAATAGCAG GCATGCTGGGGGGGCGGCCGCAGGAACCCTAGTGATGGAGTGGCTCCCCCC TTTTGGGGGGGGGG